Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study

作者：Nira A. Krasnow, Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie H. Zhou, Samantha Fisch, Lauren Boreta, Steve Braunstein, Manish K. Aghi, Hemali Batra-Sharma, Melanie Majure, A. Jo Chien, Hope S. Rugo, Ramin A. Morshed, Harish N. Vasudevan, Michelle Melisko, Laura A. Huppert · 发表于：Breast Cancer Research · 年份：2025 · DOI：10.1186/s13058-025-02121-7 · 被引用次数：1 · 研究领域：Brain Metastases and Treatment、Lung Cancer Research Studies、Lung Cancer Treatments and Mutations

BACKGROUND: Approximately 20–30% of patients with metastatic breast cancer (MBC) develop brain metastases (BM) over the course of their disease. It is critical to better understand risk factors and survival outcomes in these patients, including those treated in the modern treatment era. METHODS: We identified patients with MBC and BM diagnosed between 1997 and 2024 at our institution. Review of medical records was completed to identify key demographic, clinical, and survival characteristics. RESULTS: We identified 507 patients with MBC and BMs with the following subtypes: HR+/HER2- (n = 184, 36.3%), HER2+ (n = 197, 38.9%), and triple negative breast cancer (TNBC; n = 126, 24.9%). Median real-world overall survival (rwOS) from the diagnosis of first BM to death was 21.6 months with the longest median rwOS in patients with HER2+ disease (31.0 months) vs. patients with HR+/HER2- (19.6 months) or TNBC (12.8 months) (p < 0.001). By date of BM diagnosis 1997–2014 vs. 2015–2024 (divided by ~ 50% of patients in each time period), patients with HER2+ and TNBC lived longer in the more modern cohort compared to prior years (HER2+: 41.2 vs. 26.2 months, p = 0.002; TNBC: 14.9 vs. 7.0 p = 0.020). There was no statistically significant difference for patients with HR+/HER2- disease (16.5 vs. 21.6, p = 0.089). On multivariable analysis, HER2+ disease (HR 0.64, 95% CI 0.50–0.81, p < 0.001), BM surgical resection (HR 0.67, 95% CI 0.51–0.87, p = 0.002), and BM diagnosis after 2014 (HR 0.77, CI ...